Stimulation of hematopoietic cells in vitro

• US 7,276,371 B2
• Filed: 12/01/2003
• Issued: 10/02/2007
• Est. Priority Date: 09/29/1997
• Status: Expired due to Fees

• Current Assignee: DARA Biosciences Incorporated (Barings LLC (Private Equity))
• Original Assignee: Point Therapeutics, Inc. (Barings LLC (Private Equity))
• Inventors: Wallner, Barbara P., Bachovchin, William
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US10/725,952
• Publication Number:
  US 20040152192A1
• Time in Patent Office: 1,401 Days
• Field of Search: 435/325, 435/377, 435/383, 424/184.1, 514/12
• US Class Current: 435/325
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/6031 Proteins
• CPC Class Codes: A61K 2039/627 characterised by the linker
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.

Claims

1. A method for stimulating hematopoietic cells in vitro comprising:

culturing the hematopoietic cells in the absence of exogenous cytokines and exogenous stromal cells and in the presence of an amount of a dipeptidylpeptidase type IV (DP IV) inhibitor sufficient to stimulate the hematopoietic cells.

2. The method of claim 1, wherein the hematopoietic cells are hematopoietic stem cells, early progenitor cells, or hematopoietic precursor cells.

3. The method of claim 1, wherein the hematopoietic cells are umbilical cord blood cells or bone marrow cells.

4. The method of claim 1, wherein the DP IV inhibitor is a Lys-boroPro monomer, a Pro-boroPro monomer, a Val-boroPro monomer or a Lys-boroPro conjugate.

5. The method of claim 1, wherein the DP IV inhibitor is an immobilized DP IV inhibitor.

6. The method of claim 5, wherein the immobilized DP IV inhibitor comprises the DP IV inhibitor attached to an immobilization structure that is a tissue culture vessel.

7. The method of claim 5, wherein the immobilized DP IV inhibitor comprises the DP IV inhibitor attached to an immobilization structure that is a particle.